Restricted accessResearch articleFirst published online 2010-07
Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer
To evaluate the clinical factors that influence pathological and clinical outcomes after preoperative concurrent chemoradiotherapy in patients with rectal cancer.
Methods
Between 1999 and 2004, 121 patients with cT3-4 or node-positive rectal cancer received preoperative chemoradiotherapy and surgery. Preoperative radiation therapy with 45 Gy was delivered. Fluorouracil-based chemotherapy was administered to most of the patients.
Results
Pathological complete remission was 14.3% after preoperative chemoradiotherapy. More than 60% tumor circumferential extent was an independent adverse factor for complete remission (P = 0.011, HR 4.643, 95% CI 1.415–15.231). Local recurrence developed in 9.9% of the cases. Serum CEA level ≥5 ng/ml (P = 0.057, HR 3.022, 95% CI 0.967–9.441) and >60% circumferential extent of tumor (P = 0.064, HR 4.232, 95% CI 0.918–19.531) were marginal adverse factors for local recurrence. Five-year disease-free survival and overall survival were 72.2% and 86.6%, respectively. Disease-free survival was poor for patients with the lymph nodes ≥1 cm in diameter (P = 0.028), cN2 stage disease (P = 0.047) and >60% circumferential extent of tumor (P = 0.058). Multivariate analysis for disease-free survival showed that the lymph node size ≥1 cm was an adverse factor (P = 0.019, HR 2.380, 95% CI 1.115–4.906). Patients with >60% circumferential extent of tumor and cN2 stage had a more unfavorable survival than the other patients (disease-free survival, P = 0.018; overall survival, P = 0.015). Patients with >60% circumferential extent of tumor and/or lymph node ≥1 cm also had an unfavorable survival (disease-free survival, P = 0.016; overall survival, P = 0.049).
Conclusions
In rectal cancer, circumferential extent of tumor and clinical lymph node status were important factors for preoperative chemoradiotherapy and surgery. A further prospective study is needed to confirm and expand these findings.
ComptonC., Fenoglio-PreiserC.M., PettigrewN., FieldingL.P.: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer, 88: 1739–1757, 2000.
2.
SauerR., BeckerH., HohenbergerW., RodelC., WittekindC., FietkauR., MartusP., TschmelitschJ., HagerE., HessC.F., KarstensJ.H., LierschT., SchmidbergerH., RaabR.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351: 1731–1740, 2004.
3.
ValentiniV., AristeiC., GlimeliusB., MinskyB.D., Beets-TanR., BorrasJ.M., HaustermansK., MaingonP., OvergaardJ., PahlmanL., QuirkeP., SchmollH.J., Sebag-MontefioreD., TaylorI., Van CutsemE., Van de VeldeC., CelliniN., LatiniP.: Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol, 92: 148–163, 2009.
4.
ValentiniV., Beets-TanR., BorrasJ.M., KrivokapicZ., LeerJ.W., PahlmanL., RodelC., SchmollH.J., ScottN., VeldeC.V., VerfaillieC.: Evidence and research in rectal cancer. Radiother Oncol, 87: 449–474, 2008.
5.
DworakO., KeilholzL., HoffmannA.: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 12: 19–23, 1997.
6.
Garcia-AguilarJ., Hernandez de AndaE., SirivongsP., LeeS.H., MadoffR.D., RothenbergerD.A.: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum, 46: 298–304, 2003.
7.
RodelC., MartusP., PapadoupolosT., FuzesiL., KlimpfingerM., FietkauR., LierschT., HohenbergerW., RaabR., SauerR., WittekindC.: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol, 23: 8688–8696, 2005.
8.
TheodoropoulosG., WiseW.E., PadmanabhanA., KernerB.A., TaylorC.W., AguilarP.S., KhandujaK.S.: T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum, 45: 895–903, 2002.
9.
PucciarelliS., ToppanP., FrisoM.L., RussoV., PasettoL., UrsoE., MarinoF., AmbrosiA., LiseM.: Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum, 47: 1798–1807, 2004.
10.
VeenhofA.A., KropmanR.H., EngelA.F., CraanenM.E., MeijerS., MeijerO.W., van der PeetD.L., CuestaM.A.: Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. Int J Colorectal Dis, 22: 507–513, 2007.
11.
GreeneF.L., PageD.L., FlemingI.D., FritzA.G., BalchC.M., HallerD.G., MorrowM.: AJCC Cancer Staging Manual, 6th edn, pp 113–123, Springer, New York, 2002.
12.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations. J Am Statist Assoc, 53: 457–481, 1958.
13.
CoxD.R.: Regression models and life tables. J Roy Stat Soc Series B, 34: 187–220, 1972.
14.
NagtegaalI.D., QuirkeP.: What is the role for the circumferential margin in the modern treatment of rectal cancer?J Clin Oncol, 26: 303–312, 2008.
15.
DetryR.J., KartheuserA.H., LagneauxG., RahierJ.: Preoperative lymph node staging in rectal cancer: a difficult challenge. Int J Colorectal Dis, 11: 217–221, 1996.
16.
DworakO.: Number and size of lymph nodes and node metastases in rectal carcinomas. Surg Endosc, 3: 96–99, 1989.
17.
KimJ.H., BeetsG.L., KimM.J., KesselsA.G., Beets-TanR.G.: Highresolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size?Eur J Radiol, 52: 78–83, 2004.
18.
KohD.M., ChauI., TaitD., WotherspoonA., CunninghamD., BrownG.: Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int J Radiat Oncol Biol Phys, 71: 456–461, 2008.
19.
DasP., SkibberJ.M., Rodriguez-BigasM.A., FeigB.W., ChangG.J., WolffR.A., EngC., KrishnanS., JanjanN.A., CraneC.H.: Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer, 109: 1750–1755, 2007.
Diaz-GonzalezJ.A., CalvoF.A., CortesJ., Garcia-SabridoJ.L., Gomez-EspiM., Del ValleE., Munoz-JimenezF., AlvarezE.: Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys, 64: 1122–1128, 2006.
22.
LinA.Y., WongW.D., ShiaJ., MinskyB.D., TempleL.K., GuillemJ.G., PatyP.B., WeiserM.R.: Predictive clinicopathologic factors for limited response of T3 rectal cancer to combined modality therapy. Int J Colorectal Dis, 23: 243–249, 2008.
23.
KimN.K., BaikS.H., MinB.S., PyoH.R., ChoiY.J., KimH., SeongJ., KeumK.C., RhaS.Y., ChungH.C.: A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Int J Radiat Oncol Biol Phys, 67: 204–210, 2007.
24.
KimY.H., KimD.Y., KimT.H., JungK.H., ChangH.J., JeongS.Y., SohnD.K., ChoiH.S., AhnJ.B., KimD.H., LimS.B., LeeJ.S., ParkJ.G.: Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys, 62: 761–768, 2005.
25.
DasP., LinE.H., BhatiaS., SkibberJ.M., Rodriguez-BigasM.A., FeigB.W., ChangG.J., HoffP.M., EngC., WolffR.A., DelclosM.E., KrishnanS., JanjanN.A., CraneC.H.: Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys, 66: 1378–1383, 2006.
26.
de la TorreA., Garcia-BerrocalM.I., AriasF., MarinoA., ValcarcelF., MagallonR., RegueiroC.A., RomeroJ., ZapataI., de la FuenteC., Fernandez-LizarbeE., VergaraG., BelinchonB., VeirasM., MoleronR., MillanI.: Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Biol Phys, 70: 102–110, 2008.
27.
KimD.Y., JungK.H., KimT.H., KimD.W., ChangH.J., JeongJ.Y., KimY.H., SonS.H., YunT., HongC.W., SohnD.K., LimS.B., ChoiH.S., JeongS.Y., ParkJ.G.: Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 67: 378–384, 2007.
28.
KwokH., BissettI.P., HillG.L.: Preoperative staging of rectal cancer. Int J Colorectal Dis, 15: 9–20, 2000.
29.
BipatS., GlasA.S., SlorsF.J., ZwindermanA.H., BossuytP.M., StokerJ.: Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging – a meta-analysis. Radiology, 232: 773–783, 2004.
30.
KantorovaI., LipskaL., BelohlavekO., VisokaiV., TrubacM., SchneiderovaM.: Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med, 44: 1784–1788, 2003.
31.
BonnenM., CraneC., VautheyJ.N., SkibberJ., DelclosM.E., Rodriguez-BigasM., HoffP.M., LinE., EngC., WongA., JanjanN.A., FeigB.W.: Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys, 60: 1098–1105, 2004.
32.
Habr-GamaA., PerezR.O., NadalinW., SabbagaJ., RibeiroU.Jr., Silva e SousaA.H.Jr., CamposF.G., KissD.R., Gama-RodriguesJ.: Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg, 240: 711–717; discussion 717–718, 2004.
